Welcome Stockaholics!

We are a new and fast growing financial forum! Sign up for free and let's talk stocks!

  1. Do you want to help develop this community? We are looking for contributions from investors and traders like you! What stocks do you follow? What is hot right now? Sign up and get in on the ground floor of the newest, fastest growing financial forum!
    Dismiss Notice
  2. You will notice a live chat widget on the right. Click in to join us and lets hear about how you nailed that last UWTI trade!
    Dismiss Notice

EVOK -- Evoke Pharma

Discussion in 'Stock Message Boards NYSE, NASDAQ, AMEX' started by Biotechmaster, Nov 12, 2019.

  1. Biotechmaster

    Biotechmaster Member

    Joined:
    Jun 3, 2016
    Messages:
    228
    Likes Received:
    5
    CHEAPEST FDA Play with MASSIVE upside potential .stock is still under radar but this will change once they resubmit the NDA in this Quarter .

    MEGA Drug targeting a $3+ BILLION Market is close to NDA-Resubmission expected before year end with potential FDA approval in Q2 .Market cap of $21 million is a PURE GIFT , this low float stock could run to $4+ even BEFORE FDA Decision . Now is the perfect time to load up before the news about NDA resubmission hit the wire which likely will attract more new investors .GL


    Evoke Pharma (EVOK)

    Market-Cap: $21 Million
    Cash: $6.5 Million
    Price: $0.87

    Shares Out: 24.1 Million


    Presentation
    https://evokepharmainc.gcs-web.com/static-files/0f21016a-d472-4005-a293-dd8d02a857e7


    •Gimoti™: Novel nasal delivery of metoclopramide for the symptomatic relief of acute and recurrent diabetic gastroparesis in women

    •Large market opportunity:~12-16M patients with symptoms (80% women); ~2-3M currently treated in US given limited efficacy from few available treatment options

    •Only one FDA-approved therapy for gastroparesis: Metoclopramide (oral & IV) still has ~4M prescriptions of the oral medication prescribed annually

    •Positive data from pivotal comparative exposure PK study: Gimoti demonstrated AUC equivalence

    •Estimated $3-4B prescription market

    •Resubmission of 505(b)(2) NDA expected Q4 2019

    If approved, Gimoti would be the first non-oral pharmacotherapy for gastroparesis approved in 40 years; metoclopramide is currently available in oral and injectable formulations.



    Evoke Pharma Signs Commercial and Financial Agreement for its Lead Product Gimoti™ in the U.S. with Novos Growth Partners
    https://www.globenewswire.com/news-...ti-in-the-U-S-with-Novos-Growth-Partners.html


    Größten Aktionäre

    Latterell ...2.1M
    Michigan ...400.0K
    Garner (Cam L) ...335.6K
    Gonyer (David A) ...319.5K
    D’Onofrio ...238.8K
    The Vanguard ...224.8K
    Geode Capital ...107.4K
    Creative ...100.0K
    Virtu Americas LLC ...70.3K
    Citadel LLC ...59.0K



    [​IMG]


    [​IMG]
     
  2. Biotechmaster

    Biotechmaster Member

    Joined:
    Jun 3, 2016
    Messages:
    228
    Likes Received:
    5
    Looking good , this low float stock could hit $2++ very quickly
     
  3. Biotechmaster

    Biotechmaster Member

    Joined:
    Jun 3, 2016
    Messages:
    228
    Likes Received:
    5
    could breakout anytime now

    [​IMG]
     
  4. Biotechmaster

    Biotechmaster Member

    Joined:
    Jun 3, 2016
    Messages:
    228
    Likes Received:
    5
    NDA filing expected within 2-3 weeks this would boost the stock even higher ..still brutally underpriced at $26 million valuation .GL
     
  5. Biotechmaster

    Biotechmaster Member

    Joined:
    Jun 3, 2016
    Messages:
    228
    Likes Received:
    5
    strong accumulation ongoing ,could hit $2 this week .GL
     
  6. Biotechmaster

    Biotechmaster Member

    Joined:
    Jun 3, 2016
    Messages:
    228
    Likes Received:
    5
    great buying opp on this pullback ahead of the NDA resubmission which could hit the wire any day now
     
  7. Biotechmaster

    Biotechmaster Member

    Joined:
    Jun 3, 2016
    Messages:
    228
    Likes Received:
    5
    Another breakout likely may be this timegoing above $2 and higher ---GL
    [​IMG]
     

Share This Page